REGN Stockholders May Be Entitled to Lead the Class Action Lawsuit Against Regeneron Pharmaceuticals, Inc. - Contact Robbins LLP for Information About Becoming the Lead Plaintiff

Robbins LLP is reminding investors who purchased Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025, and May 15, 2026, about a securities class action lawsuit. The lawsuit alleges that Regeneron misled investors regarding its Phase 3 Fianlimab-Libtayo clinical trial for advanced melanoma, specifically concerning flaws in statistical assumptions and lack of clinical differentiation. Investors who suffered losses during this period have until September 14, 2026, to seek appointment as lead plaintiff.